Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A European Clinical Trial to Evaluate PEC-Direct (Human Stem Cell-derived Implants) in Type 1 Diabetes Patients

Next Previous
X
Search
Trial Profile

A European Clinical Trial to Evaluate PEC-Direct (Human Stem Cell-derived Implants) in Type 1 Diabetes Patients

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 28 Jan 2019

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Pancreatic beta cell replacement therapy-ViaCyte (Primary)
  • Indications Type 1 diabetes mellitus
  • Focus Pharmacodynamics; Therapeutic Use

    • Most Recent Events

    • 28 Jan 2019 New trial record
    • 21 Jan 2019 According to a ViaCyte media release, this clinical trial and associated preclinical studies in Europe, are undertaken by the Beta Cell Therapy Consortium, with support of a Horizon 2020 grant from the European Commission.
    • 21 Jan 2019 According to a ViaCyte media release, the Center for Beta Cell Therapy in Diabetes and ViaCyte today announced that a human stem cell-derived product candidate PEC-Direct (also known as VC-02) has been implanted in type 1 diabetes patients at a subtherapeutic dose, in this European clinical trial.The implantation was performed at UZ Brussel, the University Hospital of Vrije Universiteit Brussel (VUB) with the PEC-Direct product candidate from ViaCyte.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top